Cerus Corp (CERS) presents a deeply negative liquidation recovery posture as of March 31, 2026. Applying standard haircuts to the reported asset base: cash and restricted cash of approximately $28.5M recovers at par; short-term investments (AFS securities) of $52.6M recover near par given mostly sub-12-month maturities; accounts receivable of $29.3M recovers at ~90-95% (~$27-28M); inventory of $61.1M current plus $15.7M noncurrent recovers at ~60% (~$46M); PP&E net of $9.2M recovers at ~50-70% (~$5-6M); intangibles/goodwill of $1.3M goodwill and $9.5M ROU asset recovers at zero; other noncurrent assets of $11.2M largely unrecoverable at liquidation. Total haircut-adjusted asset recovery approximates $175-180M. Against this, total liabilities stand at $154.6M at face value, including $84.9M in gross secured debt (MidCap term loan and revolver), $12.5M operating lease liability, $31.8M accounts payable, $18.3M accrued liabilities, and $5.4M other noncurrent liabilities. The liability stack consumes the vast majority of recoverable asset value, leaving equity recovery of roughly $20-25M before any wind-down costs, transaction friction, or contingent claims. MFFAIS-reported CLV of negative $88.9M and LLV of negative $59.6M bracket this estimate, with divergence likely attributable to treatment of noncurrent inventory and investment classification. The OLV of positive $1.5M reflects the narrow operating income position ($-354K operating loss in Q1 2026) but is not indicative of liquidation recovery. Material liquidity concerns center on the MidCap term loan: principal amortization commences April 1, 2026 unless the company exercises its option to delay to April 2027, with full maturity in March 2028. The $52.4M current portion of secured debt dominates the current liability stack of $107.4M against current assets of $175.3M. Government contract revenue from BARDA is operationally critical but carries no liquidation value as it extinguishes on wind-down. The red blood cell program, which absorbs meaningful R&D spend ($14.5M in Q1 2026), has zero intangible asset recovery value and ongoing regulatory setbacks (CBG MDR closure, new ANSM submission) further reduce any strategic option value. Accumulated deficit is $1.08B. The filing does not separately XBRL-tag BARDA receivables or deferred BARDA revenue beyond the ContractWithCustomerLiabilityCurrent tag of $1.7M.
▼ Community Notes